
Opinion|Videos|May 21, 2025
Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05
Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to potentially prevent brain metastases.
Advertisement
Episodes in this series

Clinical Brief: Novel Clinical Trial Data in HER2-Positive (HER2+) Metastatic Breast Cancer
Key Themes:
- HER2CLIMB-02 Results: Addition of tucatinib to T-DM1 showed modest progression-free survival (PFS) improvement (9.5 vs 7.4 months) without overall survival benefit
- Subgroup Benefit: More pronounced benefit observed in patients with brain metastases (PFS, 7.8 vs 5.7 months)
- HER2CLIMB-05 Trial: Investigating tucatinib added to maintenance trastuzumab/pertuzumab following first-line THP
Key Points for Physicians:
- HER2CLIMB-02 results support the concept of dual HER2-directed therapy but may not substantially change practice
- The more notable benefit in patients with brain metastases reinforces tucatinib’s value in this population
- HER2CLIMB-05 data may provide insight into whether earlier tucatinib exposure could prevent development of brain metastases
Notable Insights:
- Not all positive trial results immediately change clinical practice, particularly when the benefit is modest
- The field is moving toward bringing effective agents into earlier lines of therapy
- The potential to prevent brain metastases through earlier use of agents with central nervous system (CNS) activity represents an important research direction
Clinical Significance:
Although HER2CLIMB-02 data showed modest benefit overall, the study results reinforce tucatinib’s value in patients with brain metastases and highlight the ongoing evolution of treatment sequencing in HER2+ metastatic breast cancer, with increasing interest in preventive strategies for CNS disease.
Advertisement
Related to this article

Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.

Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5

